—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Lantheus Holdings Inc (LNTH) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for LNTH, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 56/100 · S&P 500 fund at 61, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-15
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 85th percentile of the window, -2.5% over 20 sessions. Factor regime → 2026-10-15
  • Sector × region Health care in US: +5.4% week · +6.0% month · +10.4% quarter · +24.2% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-15
  • Sovereign pressure Index -0.32 · down 0.76 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-14
How it trades on rate days beta 0.34 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How LNTH has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.34 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Lantheus Holdings Inc moved 0.34% on average · correlation 0.10 · higher than 26% of US names
  • Beta, last 3 months 0.28 about the same as over the year
  • On the 10 worst bond days −0.46% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.25% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 6 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against LNTH on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Lantheus Holdings Inc

LNTH in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Lantheus develops diagnostic and therapeutic products used in imaging and treating heart disease, cancer and other conditions. Its portfolio includes DEFINITY for echocardiography, TechneLite and Xenon-133 for nuclear medicine, and PYLARIFY, a PET imaging agent used to detect prostate cancer. It also markets RELISTOR for opioid-induced constipation and develops several radiopharmaceutical therapy candidates still in testing. The company is based in Bedford, United States.
Where it sits in the stack
Lantheus sits outside our AI build-out index; it belongs to the healthcare sector, within the specialty pharmaceuticals and diagnostic imaging sleeve of our wider universe.
Who it is priced against
Closelooknet's peer group is not set for this name; the comparison the market draws is with Novartis's radioligand therapy business.
Why Closelooknet tracks it
Lantheus holds no seat in our indices and carries no Closelooknet score yet; the diary has not quoted it in any edition.
What the diary watches
Whether its pipeline of radiopharmaceutical imaging and therapy candidates, such as PNT2002 and PNT2003, advances toward approval and adds new revenue lines.

Lantheus Holdings Inc (LNTH) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 59/100 composite (momentum 66, quality 73, valuation 54) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by Mizuho, 2026-10-13

The Street on this name

Analyst actions and the latest print for LNTH from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Mizuho — target 109 Target set to $109 (+8.9% to spot) 2026-10-13
  • Downgrade B. Riley — Buy → Neutral Downgraded to Neutral from Buy 2026-08-17

2 actions on the analyst wire since 2026-08-13: 1 downgrade, 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 300 m USD in FY2025

Dividends and capital return

What LNTH pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 300 m USD 4.6% of today's market value
  • Share count −4.5% in FY2025 86 m USD of stock-based compensation in the year
  • Capital returned 300 m USD · 85% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-16

Quick answers

What is Lantheus Holdings Inc (LNTH)?

Lantheus Holdings Inc trades as LNTH on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-16.

Is LNTH in a Closelooknet index?

Not currently — Lantheus Holdings Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-16.

What is Lantheus Holdings Inc's Closelooknet composite score?

59 out of 100, with momentum 66, quality 73 and valuation 54 sub-scores, as of 2026-10-16. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does LNTH trade against its moving averages?

Pullback inside an uptrend stack: Trades -0.4% vs the 50-day and +11.6% vs the 200-day average, 10.6% below the 52-week high and +99.4% off the 52-week low. Computed from daily closes. As of 2026-10-15 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Lantheus Holdings Inc compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic · US), Lantheus Holdings Inc (LNTH) sits 10.6% below its 52-week high, 0.4% below its 50-day average; Kiniksa Pharmaceuticals Ltd (KNSA) is 3.7% below, GALDERMA GROUP AG (GALDY) is 10.2% below, Alkermes Plc (ALKS) is 28.0% below. Put any of them next to LNTH in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Lantheus Holdings Inc trade when bond yields rise?

Over the past year Lantheus Holdings Inc had a beta of 0.34 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 26% of US names. On the 10 sessions in which long bonds fell most it moved −0.46% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Lantheus Holdings Inc do?

Lantheus develops diagnostic and therapeutic products used in imaging and treating heart disease, cancer and other conditions. Its portfolio includes DEFINITY for echocardiography, TechneLite and Xenon-133 for nuclear medicine, and PYLARIFY, a PET imaging agent used to detect prostate cancer. It also markets RELISTOR for opioid-induced constipation and develops several radiopharmaceutical therapy candidates still in testing. Closelooknet's peer group is not set for this name; the comparison the market draws is with Novartis's radioligand therapy business.

Where does Lantheus Holdings Inc sit in the AI build-out?

Lantheus sits outside our AI build-out index; it belongs to the healthcare sector, within the specialty pharmaceuticals and diagnostic imaging sleeve of our wider universe. Lantheus holds no seat in our indices and carries no Closelooknet score yet; the diary has not quoted it in any edition.

Does Lantheus Holdings Inc pay a dividend?

No cash distribution shows in Lantheus Holdings Inc’s price series over the last three years. In fiscal 2025 the company bought back 300 m USD of its own shares, 85% of that year’s free cash flow. The share count fell 4.5% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Lantheus Holdings Inc recently?

The most recent analyst action on Lantheus Holdings Inc on the Closelooknet wire is a price target by Mizuho on 2026-10-13 (target 109). 2 actions on the analyst wire since 2026-08-13: 1 downgrade, 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for LNTH, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.